$0.81
▲ +3.9% Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
Overview
52-week range
$0.39
$3.87
12% of range
Avg surprise (last 3)
+12.9%
Avg reaction (last 2)
-12.0%
0% positive
Latest IV / EM
115%
EM ±19.2% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.04 | $-0.06 | +33.3% | +81.8% | -2.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.18 | $-0.19 | +5.3% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.22 | $-0.22 | 0.0% | — | -21.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.29 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.36 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.37 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.05 | -$0.18 | +72.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | — | $0 | $0 | $172,000 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-8M | — | $-7M | $-11M | $-12M | — | $-12M | $-13M |
| Net income | $-7M | — | $-5M | $-7M | $-7M | — | $-7M | $-7M |
| EPS (diluted) | $-0.04 | — | $-0.12 | $-0.18 | $-0.22 | — | $-0.24 | $-0.26 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10M | $19M | $4M | $10M | $10M | $4M | $4M | $5M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $47M | $53M | $5M | $11M | $18M | $30M | $32M | $32M |
| Total assets | $52M | $59M | $10M | $17M | $24M | $37M | $44M | $44M |
| Long-term debt | — | — | $0 | $2M | $6M | $10M | $14M | $17M |
| Total liabilities | $16M | $17M | $22M | $26M | $29M | $33M | $38M | $38M |
| Total equity | $28M | $33M | $-8M | $-6M | $-3M | $2M | $3M | $3M |